Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8927227 | 0.88 | HTR2C (0.49) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL14088038 | 0.74 | NCOA1 (0.41) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL9618314 | 0.74 | HTR2A (0.45) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL30310107 | 0.70 | HTR2C (0.45) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL30310105 | 0.70 | HTR2C (0.45) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL28975718 | 0.68 | KDM4E (0.38) | MAOA | |
| SCHEMBL4429415 | 0.67 | PAX8 (0.48) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| SCHEMBL13983903 | 0.65 | HTR2C (0.66) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL634543 | 0.65 | HSD17B10 (0.42) | HTR2CHTR2AHTR1ANFKB1 | |
| SCHEMBL31668742 | 0.65 | HSD17B10 (0.42) | HTR2CHTR2AHTR1ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143103-A | Continuous preparation method of pyrroloindoline/furan indoline compound | 浙江工业大学 | 2023-12-01 | — | — | CN | claimed |
| EP-0586254-A1 | Furanoindoline derivatives and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-03-09 | — | — | EP | claimed |
| CN-117143103-B | Continuous preparation method of pyrroloindoline/furan indoline compound | 浙江工业大学 | 2025-10-21 | — | — | CN | disclosed |
| WO-2025162127-A1 | DIHYDROFUROINDOLE COMPOUND OR DERIVATIVE THEREOF AND USE THEREOF | 深壶制药(山东)有限公司 | 2025-08-07 | — | — | WO | disclosed |
| WO-2025162127-A1 | DIHYDROFUROINDOLE COMPOUND OR DERIVATIVE THEREOF AND USE THEREOF | 深壶制药(山东)有限公司 | 2025-08-07 | — | — | WO | disclosed |
| CN-120398899-A | Dihydrofuroindoles compound or derivative thereof and application thereof | 深壶制药(山东)有限公司 | 2025-08-01 | — | — | CN | disclosed |
| CN-118420616-A | Azabridged ring compound and preparation method thereof | 浙江工业大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-118271321-A | Synthetic method of indoline compound | 浙江工业大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-117143103-A | Continuous preparation method of pyrroloindoline/furan indoline compound | 浙江工业大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-117143103-A | Continuous preparation method of pyrroloindoline/furan indoline compound | 浙江工业大学 | 2023-12-01 | — | — | CN | disclosed |
| US-20230113944-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| CN-113880750-B | Synthesis method of chiral 3-substituted-3-aryl oxindole compound | 上海交通大学 | 2023-02-10 | — | — | CN | disclosed |
| EP-4087847-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | The Regents of the University of California (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-0586254-A1 | Furanoindoline derivatives and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0586254-A1 | Furanoindoline derivatives and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0586254-A1 | Furanoindoline derivatives and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5248691-A | Antitumor agent | ELI LILLY AND COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5248691-A | Antitumor agent | ELI LILLY AND COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113944-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMPD2, PSEN2, SMN1; SMN2 | HTR2C 1685/4885HTR2A 1134/4885HTR2B 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.